About Candidate Substances
While clinical trials using mesenchymal stem cells for new corona patients are being conducted in Japan and abroad, Biomimetics Sympathies has analyzed the therapeutic mechanism of new corona infection postulated by mesenchymal stem cells and found that the transcription factor FOXO1 is important for the regulation of ACE2 and TMPRSS2 gene expression. As a result of finding that FOXO1 is important for the regulation of gene expression of ACE2 and TMPRSS2, we succeeded in discovering three therapeutic drug candidates with inhibitory effects on FOXO1.
These are quite groundbreaking in that they suppress gene expression of both ACE2 and TMPRSS2, which exist on the surface of host cells and are critical for SARS-CoV2 to invade and infect host cells via its own spike protein (Figure 1). Although drugs targeting either ACE2 or TMPRSS2 have been known in the past, this discovery is unique in that it suppresses both of them with a single drug (Fig. 2).
And indeed, quinolone compound X has been shown to significantly inhibit the uptake of SARS-CoV2 S1 spike protein into host cells in in vitro studies, as well as a tendency to suppress gene expression of ACE2 or TMPRSS2 in lung tissue upon intratracheal administration to mice . Biomimetics Sympathies will further evaluate the drug for drug development, including SARS-CoV2 infection experiments, in collaboration with Rohto Pharmaceuticals.
Insulin and HGF have also been shown to simultaneously and significantly inhibit the expression of ACE2 and TMPRSS2 via a mechanism similar to that of quinolone compound X.
License Agreement
A license agreement was concluded with Rohto Pharmaceutical for quinolone compound X, which has FOXO1 inhibitory activity, and joint development will be carried out for drug development. The company and Rohto will also jointly study the commercialization of this technology.
Joint Efforts "RB+" About RB+
Biomimetics Sympathies and Rohto Pharmaceutical are launching a new research and development organization, "RB+," to expand the method of identifying drug candidates for novel coronavirus infection based on new mechanisms discovered in regenerative medicine research to the development of drugs for other diseases. RB+" is a co-creation platform that will, in the near future, elucidate the therapeutic mechanisms of many diseases targeted by mesenchymal stem cells, discover previously unknown drug targets, and accelerate the movement toward the practical application of therapeutic drugs through open innovation, inviting the participation of other companies as well.
(Figure 1)

(Figure 2)










